MicroRNA copy number alterations in the malignant transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma.
carcinoma ex pleomorphic adenoma
comparative genomic hybridization
copy number alteration
copy number variation
microRNAs
pleomorphic adenoma
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
revised:
19
02
2024
received:
08
11
2023
accepted:
20
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
This study used array comparative genomic hybridization to assess copy number alterations (CNAs) involving miRNA genes in pleomorphic adenoma (PA), recurrent pleomorphic adenoma (RPA), residual PA, and carcinoma ex pleomorphic adenoma (CXPA). We analyzed 13 PA, 4 RPA, 29 CXPA, and 14 residual PA using Nexus Copy Number Discovery software. The miRNAs genes affected by CNAs were evaluated based on their expression patterns and subjected to pathway enrichment analysis. Across the groups, we found 216 CNAs affecting 2261 miRNA genes, with 117 in PA, 59 in RPA, 846 in residual PA, and 2555 in CXPA. The chromosome 8 showed higher involvement in altered miRNAs in PAs and CXPA patients. Six miRNA genes were shared among all groups. Additionally, miR-21, miR-455-3p, miR-140, miR-320a, miR-383, miR-598, and miR-486 were prominent CNAs found and is implicated in carcinogenesis of several malignant tumors. These miRNAs regulate critical signaling pathways such as aerobic glycolysis, fatty acid biosynthesis, and cancer-related pathways. This study was the first to explore CNAs in miRNA-encoding genes in the PA-CXPA sequence. The findings suggest the involvement of numerous miRNA genes in CXPA development and progression by regulating oncogenic signaling pathways.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Coordination for the Improvement of Higher Education Personnel (CAPES)
Organisme : São Paulo Research Foundation (FAPESP)
ID : 19/09419-0
Organisme : São Paulo Research Foundation (FAPESP)
ID : 15/07304-0
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Kerche LE, de Sousa EA, Squarize CH, et al. EMT in salivary gland tumors: the expression of microRNAs miR-155 and miR-200c is associated with clinical-pathological parameters. Mol Biol Rep. 2022;49:2157-2167. doi:10.1007/s11033-021-07033-1
Mariano FV, Egal ES, Pramio D, et al. Evaluation of a subset of tumor suppressor gene for copy number and epigenitic changes in pleomorphic adenoma and carcinoma ex-pleomorphic adenoma carcinogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:322-331. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2212440316300797
Pérez-de-Oliveira ME, da Leonel ACLS, de Castro JFL, de Carvalho EJA, Vargas PA, da Perez DEC. Histopathological findings of intraoral pleomorphic adenomas: a retrospective study of a case series. Int J Surg Pathol. 2019;27:729-735. doi:10.1177/1066896919854181
Antony J, Gopalan V, Smith RA, Lam AKY. Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol. 2012;6:1-9. doi:10.1007/s12105-011-0281-z
Di Palma S. Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol. 2013;suppl 7(1):68-76. Available from: https://pubmed.ncbi.nlm.nih.gov/23821206/
Mariano FV, Noronha ALF, Gondak RO, de Altemani AM, de Almeida OP, Kowalski LP. Carcinoma ex pleomorphic adenoma in a Brazilian population: clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg. 2013;42:685. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0901502713000787d-692.
Katabi N, Ghossein R, Ho A, et al. Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Hum Pathol. 2015;46:26-33. Available from: https://pubmed.ncbi.nlm.nih.gov/25439740/
Scarini JF, Rosa LF, de Souza RAL, et al. Gene and immunohistochemical expression of HIF-1α, GLUT-1, FASN, and adipophilin in carcinoma ex pleomorphic adenoma development. Oral Dis. 2020;26:1190-1199. doi:10.1111/odi.13332
de Lima-Souza RA, Scarini JF, Lavareze L, et al. Discovery proteomics reveals potential protein signature associated with malignant phenotype acquisition in pleomorphic adenoma. Oral Dis. 2021;29:1017-1027. Available from:https://pubmed.ncbi.nlm.nih.gov/34902207/
Abu-Ghanem Y, Mizrachi A, Popovtzer A, Abu-Ghanem N, Feinmesser R. Recurrent pleomorphic adenoma of the parotid gland: institutional experience and review of the literature. J Surg Oncol. 2016;114:714-718. Available from: https://pubmed.ncbi.nlm.nih.gov/27468730/
Andreasen S, Therkildsen MH, Bjørndal K, Homøe P. Pleomorphic adenoma of the parotid gland 1985-2010: a Danish nationwide study of incidence, recurrence rate, and malignant transformation. Head Neck. 2016;38:E1364-E1369. doi:10.1002/hed.24228
Schapher M, Koch M, Agaimy A, Goncalves M, Mantsopoulos K, Iro H. Parotid pleomorphic adenomas: factors influencing surgical techniques, morbidity, and long-term outcome relative to the new ESGS classification in a retrospective study. J Cranio-Maxillofacial Surg. 2019;47:1356-1362. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1010518219300861
El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. WHO Classification Head Neck Tumours. 4th ed. IARC Press; 2017.
Ware AP, Satyamoorthy K, Paul B. CmirC: an integrated database of clustered miRNAs co-localized with copy number variations in cancer. Funct Integr Genomics. 2022;22:1229-1241. doi:10.1007/s10142-022-00909-w
Zhang X, Cairns M, Rose B, et al. Alterations in miRNA processing and expression in pleomorphic adenomas of the salivary gland. Int J Cancer. 2009;124:2855-2863. doi:10.1002/ijc.24298
Zhang L, Lu Q, Chang C. Epigenetics in health and disease. Adv Exp Med Biol. 2020;1253:3-55. doi:10.1007/978-981-15-3449-2_1
Abdolrahmani A, Kardouni Khoozestani N, Azmoudeh-Ardalan F, Shamshiri AR. Prognostic impact of MUC1 and potential regulatory miR-145 and miR-21 expression in salivary mucoepidermoid carcinoma. Head Neck Pathol. 2022;16:1134-1145. doi:10.1007/s12105-022-01475-0
Matse JH, Yoshizawa J, Wang X, et al. Discovery and prevalidation of salivary extracellular microRNA biomarkers panel for the noninvasive detection of benign and malignant parotid gland tumors. Clin Cancer Res. 2013;19:3032-3038. Available from: https://pubmed.ncbi.nlm.nih.gov/23575476/
Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev. 2009;84:55-71. doi:10.1111/j.1469-185X.2008.00061.x
Pös O, Radvanszky J, Buglyó G, et al. DNA copy number variation: main characteristics, evolutionary significance, and pathological aspects. Biomed J. 2021;44:548-559. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2319417021000093
Peng H, Lu L, Zhou Z, et al. CNV detection from circulating tumor DNA in late stage non-small cell lung cancer patients. Genes (Basel). 2019;10:926 Available from: https://www.mdpi.com/2073-4425/10/11/926
Veitia RA, Bottani S, Birchler JA. Cellular reactions to gene dosage imbalance: genomic, transcriptomic and proteomic effects. Trends Genet. 2008;24:390-397. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168952508001741
Persengiev S, Kondova I, Bontrop R. Insights on the functional interactions between miRNAs and copy number variations in the aging brain. Front Mol Neurosci. 2013;6:32. doi:10.3389/fnmol.2013.00032/abstract
Shao C, Yu Y, Yu L, et al. Amplification and up-regulation of microRNA-30b in oral squamous cell cancers. Arch Oral Biol. 2012;57:1012-1017. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0003996912001033
Saleh AD, Cheng H, Martin SE, et al. Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer. Clin Cancer Res. 2019;25:2860-2873. Available from: https://aacrjournals.org/clincancerres/article/25/9/2860/82600/Integrated-Genomic-and-Functional-microRNA
Ramachandran I, Ganapathy V, Gillies E, et al. Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis. 2014;5(5):e1246 Available from: https://www.nature.com/articles/cddis2014219
Andreasen S, Therkildsen MH, Grauslund M, Friis-Hansen L, Wessel I, Homøe P. Activation of the interleukin-6/Janus kinase/STAT3 pathway in pleomorphic adenoma of the parotid gland. APMIS. 2015;123:706-715. Available from: https://pubmed.ncbi.nlm.nih.gov/26061266/
Ianez RCF. Avaliação da via do c-kit no adenoma pleomórfico e carcinoma adenoide cístico das glândulas salivares: estudo da expressão das proteínas da via, das mutações e da regulação pós-transcricional do gene kit. 2016.
Boštjančič E, Hauptman N, Grošelj A, Glavač D, Volavšek M. Expression, mutation, and amplification status of EGFR and its correlation with five miRNAs in salivary gland tumours. Biomed Res Int. 2017;2017:1-11. Available from: https://www.hindawi.com/journals/bmri/2017/9150402/
de Flores BCT, Lourenço SV, Damascena AS, Kowaslki LP, Soares FA, Coutinho-Camillo CM. Altered expression of apoptosis-regulating miRNAs in salivary gland tumors suggests their involvement in salivary gland tumorigenesis. Virchows Arch. 2017;470:291-299. doi:10.1007/s00428-016-2049-z
Santos PRB, Coutinho-Camillo CM, Soares FA, et al. MicroRNAs expression pattern related to mast cell activation and angiogenesis in paraffin-embedded salivary gland tumors. Pathol Res Pract. 2017;213:1470-1476. Available from: https://pubmed.ncbi.nlm.nih.gov/29108921/
Brodetskyi IS, Malanchuk VO, Dosenko VE. Expressions of microRNA-29a and microRNA-34a in pleomorphic adenomas of salivary glands. Gland Surg. 2020;9:1914-1923. Available from: http://gs.amegroups.com/article/view/57469/html
Kim H, Eun S, Jeong W-J, et al. Identification of differentially expressed microRNAs as potential biomarkers for carcinoma ex pleomorphic adenoma. Sci Rep. 2022;12:13383 Available from: https://www.nature.com/articles/s41598-022-17740-9
de Morais EF, Pinheiro JC, Sena DAC, Galvão HC, de Souza LB, de Almeida FR. Extracapsular invasion: a potential prognostic marker for carcinoma ex-pleomorphic adenoma of the salivary glands? A systematic review. J Oral Pathol Med. 2019;48:433-440.
Cai X, Zhang J, Li L, et al. Copy number alterations predict development of OSCC from oral leukoplakia. J Dent Res. 2024;103:138-146. doi:10.1177/00220345231217160
Altemani A, Martins MT, Freitas L, Soares F, Araújo NS, Araújo VC. Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005;46:635-641. Available from: https://pubmed.ncbi.nlm.nih.gov/15910594/
He B, Wu C, Sun W, et al. miR-383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24-mediated NF-κB signaling pathway. Int J Oncol. 2021;59:87. doi:10.3892/ijo.2021.5267
Ma H, Liu B, Wang S, Liu J. MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1. Cell Biochem Funct. 2016;34:613-619. doi:10.1002/cbf.3237
Zhao L-N, Wang P, Liu Y-H, et al. MiR-383 inhibits proliferation, migration and angiogenesis of glioma-exposed endothelial cells in vitro via VEGF-mediated FAK and Src signaling pathways. Cell Signal. 2017;30:142-153. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0898656816302339
Xu D, Ma P, Gao G, Gui Y, Niu X, Jin B. MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. Tumor Biol. 2015;36:7743-7753. doi:10.1007/s13277-015-3378-2
Xu Z, Zeng X, Li M, Liao J, Chen Q. MicroRNA-383 promotes reactive oxygen species-induced autophagy via downregulating peroxiredoxin 3 in human glioma U87 cells. Exp Ther Med. 2021;21:439. doi:10.3892/etm.2021.9870
Xu Z, Chen Q, Zeng X, Li M, Liao J. Lnc-NLC1-C inhibits migration, invasion and autophagy of glioma cells by targeting miR-383 and regulating PRDX-3 expression. Oncol Lett. 2021;22:640. doi:10.3892/ol.2021.12901
He Z, Cen D, Luo X, et al. Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol. 2013;30:557. doi:10.1007/s12032-013-0557-0
Li J, Smith AR, Marquez RT, et al. MicroRNA-383 acts as a tumor suppressor in colorectal cancer by modulating CREPT/RPRD1B expression. Mol Carcinog. 2018;57:1408-1420. doi:10.1002/mc.22866
Han RL, Wang FP, Zhang PA, Zhou XY, Li Y. miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic glycolysis by targeting LDHA. Neoplasma. 2017;64:244-252. Available from: http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=5061&category_id=133&option=com_virtuemart
Li KK-W, Pang JC-S, Lau K-M, et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013;23:413-425. doi:10.1111/bpa.12014
Shang Y, Zang A, Li J, et al. MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner. Biomed Pharmacother. 2016;83:1175-1181. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332216308502
Su Q-L, Zhao H-J, Song C-F, Zhao S, Tian Z-S, Zhou J-J. MicroRNA-383 suppresses pancreatic carcinoma development via inhibition of GAB1 expression. Eur Rev Med Pharmacol Sci. 2019;23:10729-10739. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31858540
Bucay N, Sekhon K, Yang T, et al. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene. 2017;36:2667-2679. Available from: https://www.nature.com/articles/onc2016419
Wang X, Ren Y, Wang Z, et al. Down-regulation of 5S rRNA by miR-150 and miR-383 enhances c-Myc-rpL11 interaction and inhibits proliferation of esophageal squamous carcinoma cells. FEBS Lett. 2015;589:3989-3997. doi:10.1016/j.febslet.2015.11.012
Liu C, Yu Z, Huang S, et al. Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC. EBioMedicine. 2019;50:135-143. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352396419307650
Huang H, Tian H, Duan Z, Cao Y, Zhang X-S, Sun F. microRNA-383 impairs phosphorylation of H2AX by targeting PNUTS and inducing cell cycle arrest in testicular embryonal carcinoma cells. Cell Signal. 2014;26:903-911. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0898656814000357
Qi L, Gao C, Feng F, et al. MicroRNAs associated with lung squamous cell carcinoma: new prognostic biomarkers and therapeutic targets. J Cell Biochem. 2019;120:18956-18966. doi:10.1002/jcb.29216
Ma Y, Yan F, Wei W, et al. MicroRNA-598 inhibits the growth and maintenance of gastric cancer stem-like cells by down-regulating RRS1. Cell Cycle. 2019;18:2757-2769. doi:10.1080/15384101.2019.1657338
Chen J, Zhang H, Chen Y, et al. miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell Res. 2017;352:104-112. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014482717300459
Tong X, Su P, Yang H, et al. MicroRNA-598 inhibits the proliferation and invasion of non-small cell lung cancer cells by directly targeting ZEB2. Exp Ther Med. 2018;24:528. doi:10.3892/etm.2018.6825
Xing F, Wang S, Zhou J. The expression of MicroRNA-598 inhibits ovarian cancer cell proliferation and metastasis by targeting URI. Mol Ther Oncolytics. 2019;12:9-15. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2372770518300378
Liu F, Zhang Q, Liang Y. MicroRNA-598 acts as an inhibitor in retinoblastoma through targeting E2F1 and regulating AKT pathway. J Cell Biochem. 2020;121:2294-2302. doi:10.1002/jcb.29453
Zhang W, Yang H, Wang Z, et al. miR-320a/SP1 negative reciprocal interaction contributes to cell growth and invasion in colorectal cancer. Cancer Cell Int. 2021;21:175. doi:10.1186/s12935-021-01874-3
Khandelwal A, Sharma U, Barwal TS, et al. Circulating miR-320a acts as a tumor suppressor and prognostic factor in non-small cell lung cancer. Front Oncol. 2021;11:64547. doi:10.3389/fonc.2021.645475/full
Hong H, Zhu H, Zhao S, et al. The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression. Cell Death Dis. 2019;10:950 Available from: http://www.nature.com/articles/s41419-019-2183-z
Lv Q, Hu J-X, Li Y-J, et al. MiR-320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals. Cancer Biol Ther. 2017;18:142-151. doi:10.1080/15384047.2017.1281497
Xie F, Yuan Y, Xie L, et al. miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther. 2017;10:885-894. Available from: https://www.dovepress.com/mirna-320a-inhibits-tumor-proliferation-and-invasion-by-targeting-c-my-peer-reviewed-article-OTT
Ge X, Cui H, Zhou Y, et al. miR-320a modulates cell growth and chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med Rep. 2017;16:9664-9670. doi:10.3892/mmr.2017.7819
Xie N, Wang C, Zhuang Z, et al. Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma. Oncotarget. 2016;7:65744-65757. doi:10.18632/oncotarget.11612
Wang Y, Yang J, Chen P, et al. MicroRNA-320a inhibits invasion and metastasis in osteosarcoma by targeting cytoplasmic polyadenylation element-binding protein 1. Cancer Med. 2020;9:2833-2845. doi:10.1002/cam4.2919
Bi X, Jiang Z, Luan Z, Qiu D. Crocin exerts anti-proliferative and apoptotic effects on cutaneous squamous cell carcinoma via miR-320a/ATG2B. Bioengineered. 2021;12:4569-4580. doi:10.1080/21655979.2021.1955175
Wang W, Zhao L, Wei X, et al. MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells. Sci Rep. 2016;6:27641 Available from: http://www.nature.com/articles/srep27641
Guled M, Pazzaglia L, Borze I, et al. Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: a miRNA analysis. Genes Chromosomes Cancer. 2014;53:693-702. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24771630
Liu J, Dou Y, Sheng M. Inhibition of microRNA-383 has tumor suppressive effect in human epithelial ovarian cancer through the action on caspase-2 gene. Biomed Pharmacother. 2016;83:1286-1294. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332216307557
Wan P, Chi X, Du Q, et al. miR-383 promotes cholangiocarcinoma cell proliferation, migration, and invasion through targeting IRF1. J Cell Biochem. 2018;119:9720-9729. doi:10.1002/jcb.27286
Tu C, Chen W, Wang S, et al. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2. J Cell Mol Med. 2019;23:7190-7199. doi:10.1111/jcmm.14197
Wang M, Wen T-F, He L-H, Li C, Zhu W-J, Trishul NM. A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med. 2015;8:17261-17270. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26770318
Li K, Fang Y, Liao J, et al. Upregulation of miR-598 promotes cell proliferation and cell cycle progression in human colorectal carcinoma by suppressing INPP5E expression. Mol Med Rep. 2018;17:2991-2997. doi:10.3892/mmr.2017.8207
Sha C, Jia G, Jingjing Z, Yapeng H, Zhi L, Guanghui X. miR-486 is involved in the pathogenesis of acute myeloid leukemia by regulating JAK-STAT signaling. Naunyn Schmiedebergs Arch Pharmacol. 2021;394:177-187. doi:10.1007/s00210-020-01892-4
Seyyedi SS, Soleimani M, Yaghmaie M, et al. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics. Tumor Biol. 2016;37:4841-4847. doi:10.1007/s13277-015-4289-y
Li C, Wang Y, Wang H, et al. miR-486 promotes the invasion and cell cycle progression of ovarian cancer cells by targeting CADM1. Anal Cell Pathol. 2021;2021:1-13. Available from: https://www.hindawi.com/journals/acp/2021/7407086/
Gao Z-J, Yuan W-D, Yuan J-Q, Yuan K, Wang Y. miR-486 as an unfavorable prognostic biomarker for patients with non-small cell lung cancer. Transl Cancer Res. 2020;9:104-110. Available from: http://tcr.amegroups.com/article/view/33496/html
Li W, Wang Y, Zhang Q, et al. MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One. 2015;10:e0134220. doi:10.1371/journal.pone.0134220
Sun C, Sun C, Zhou Y, et al. miR-486 acts as an oncogene and potential prognostic biomarker in renal cell carcinoma. Mol Med Rep. 2019;20:5208-5215. doi:10.3892/mmr.2019.10769
Xia L, Song M, Sun M, Chen W, Yang C. miR-486 promotes Capan-2 pancreatic cancer cell proliferation by targeting phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Front Genet. 2019;10:541. Available from: https://www.frontiersin.org/article/10.3389/fgene.2019.00541/full
Lerebours F, Cizeron-Clairac G, Susini A, et al. miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness. Int J Cancer. 2013;133:1614-1623. doi:10.1002/ijc.28171
Sromek M, Glogowski M, Chechlinska M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. Cell Oncol. 2017;40:529-536. doi:10.1007/s13402-017-0334-8
Mozzoni P, Banda I, Goldoni M, et al. Plasma and EBC microRNAs as early biomarkers of non-small-cell lung cancer. Biomarkers. 2013;18:679-686. doi:10.3109/1354750X.2013.845610
Borjigin N, Ohno S, Wu W, et al. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma. Biochem Biophys Res Commun. 2012;427:355-360. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006291X12018037
Lang B, Zhao S. miR-486 functions as a tumor suppressor in esophageal cancer by targeting CDK4/BCAS2. Oncol Rep. 2018;39:71-80. doi:10.3892/or.2017.6064
Peng Y, Dai Y, Hitchcock C, et al. Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci. 2013;110:15043-15048. doi:10.1073/pnas.1307107110
Yang N, Liang Y, Yang P, Yang T, Jiang L. Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression. Brazilian J Med Biol Res. 2017;50:50. Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2017000100601&tlng=en
Liu Y, Zhang J, Xing C, Wei S, Guo N, Wang Y. miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting PIM1. Cancer Biomarkers. 2018;23:269-277. doi:10.3233/CBM-181527
He M, Wang G, Jiang L, et al. miR-486 suppresses the development of osteosarcoma by regulating PKC-δ pathway. Int J Oncol. 2017;50:1590-1600. doi:10.3892/ijo.2017.3928
Wu H, Xia L, Xu H. Role of FUS-CHOP in myxoid liposarcoma via miR-486/CDK4 Axis. Biochem Genet. 2022;60:1095-1106. doi:10.1007/s10528-021-10151-x
Oh H-K, Tan AL-K, Das K, et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res. 2011;17:2657. Available from: https://aacrjournals.org/clincancerres/article/17/9/2657/12973/Genomic-Loss-of-miR-486-Regulates-Tumor-2667.
Zhou J, Liu X, Wang C, Li C. The correlation analysis of miRNAs and target genes in metastasis of cervical squamous cell carcinoma. Epigenomics. 2018;10:259-275. doi:10.2217/epi-2017-0104
Sun Y-H, Liu Z-F, Yang B-B, Yu B. MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2019;23:8429-8439. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31646573
Key S, Chia C, Hasan Z, Sundaresan P, Riffat F, Dwivedi RC. Molecular factors in carcinoma ex pleomorphic adenoma: systematic review and meta-analysis. Laryngoscope. 2024;134:1042-1053. doi:10.1002/lary.30993
DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:2.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867411001279
de Lima-Souza RA, de Rodrigues NM, Scarini JF, et al. Metabolic alterations in carcinoma ex pleomorphic adenoma development of lacrimal glands. Int Ophthalmol. 2022;42:1101-1109. doi:10.1007/s10792-021-02096-2
de Angelis CM, de Lima-Souza RA, Scarini JF, et al. Immunohistochemical expression of fatty acid synthase (FASN) is correlated to tumor aggressiveness and cellular differentiation in salivary gland carcinomas. Head Neck Pathol. 2021;15:1119-1126.
Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73:377-392.